BIOPTIMUS
20.2.2024 09:01:26 CET | Business Wire | Press release
Today, French startup Bioptimus emerged from stealth following a seed funding round of $35M. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model technologies that capture the various scales of biology. This funding round is led by Sofinnova Partners, with Bpifrance Large Venture, and additional support from global funds based in France, including Frst and multistage VC Cathay Innovation. Top global tech investors Headline, Hummingbird, NJF Capital, Owkin and Top Harvest Capital, as well as notable tech entrepreneur Xavier Niel, have joined the round to create a global leader in AI for biology in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220205004/en/
Professor Jean-Philippe Vert, PhD, co-founder and CEO of Bioptimus, Chief R&D Officer of Owkin and former Research Lead at Google Brain, said: “The application of foundation models and generative AI to biology is set to have a profound impact in science. By harnessing the power of foundation models and advanced algorithms trained on massive amounts of biological and multimodal data across scales, we aim to capture the laws of biology that have hitherto remained too complex to be properly understood. This holistic understanding of biology across scales will be critical to accelerate biomedical and environmental science.”
Edward Kliphuis, Partner at Sofinnova Partners, added: “Foundation models in biology are game-changers. They unlock unprecedented potential to personalize medicine, capturing the uniqueness of each individual while harnessing the collective knowledge of all. Bioptimus stands out by seamlessly blending unparalleled data resources and access, elite talent, and extensive computational power. Together with Sofinnova's deep expertise in life sciences and our expansive network, we're poised to redefine the future of the industry."
Laurent Higueret, Senior Investment Director at Bpifrance Large Venture, commented: “Founded on the ambition to make a quantum leap in our understanding of the complexity of human biology and bringing together a top team of accomplished experts in the fields of data science and generative AI, Bioptimus holds the promise to go even deeper in the analysis of patients’ data across multiple levels and help unveil biological connections hitherto unthought-of. We at Bpifrance are delighted to team-up with such an impressive team and group of investors and support the development of a category defining company that has the potential to disrupt many R&D activities.”
Bioptimus will benefit from Owkin’s data generation capabilities and federated global access to multimodal patient data sourced from leading academic hospitals worldwide, as well as a best-in-class, scalable and secure computing environment from Amazon Web Services, Inc (AWS). Fueled by an abundance of data from all scales and modalities, this gives the power to create computational representations that establish a strong differentiation against models trained solely on public datasets and a single data modality that are not able to capture the full diversity of biology.
About Bioptimus
Bioptimus is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies and accessing unique proprietary data at scale, we aim to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. For more information, please visit https://www.bioptimus.com.
About Owkin
Owkin is a TechBio company that combines the best of human and artificial intelligence to ensure every patient gets the right treatment. By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials and develop AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI’s potential to power precision medicine. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation. Owkin founded MOSAIC, the world’s largest multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and Bpifrance, among others).
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners invests in companies from seed to late-stage, and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop innovations that will positively impact our collective future.
Founded in 1972, Sofinnova Partners has backed over 500 companies and created market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
About Bpifrance and its Large Venture fund
Bpifrance is the French Public Investment Bank and acts as one-stop-shop offering domestic companies a comprehensive range of financial products and services to support them at every stage of their development including equity, loans, guarantees and export insurances, as well as consultancy or training.
Large Venture - the late-stage VC arm of Bpifrance - is a €1.75 billion fund dedicated to fast-growing, highly innovative startups looking to accelerate organic or external growth. Large Venture was incepted in 2013 with the mission to bring the most promising French technologies from the lab to the market, and ultimately to profitability. Large Venture invests in private and public companies across three main sectors: healthtech and life sciences, digital and greentech. For more information, please visit us at: bpifrance.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220205004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches World’s Smallest RF / Microwave Coaxial Connectors with a Switch, Cutting PCB Mounting Area by Approximately 40%29.10.2026 03:00:00 CET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of the SWL series MM8330-2600RJ5 and MM8330-2600RK20, the world’s smallest RF / microwave coaxial connectors with a switch*. Measuring just 1.0 mm × 1.0 mm × 0.55 mm, the new connectors reduce PCB mounting area by approximately 40% compared with Murata’s previous SWJ series. When used with dedicated probes, the SWL series reduces its PCB footprint, including the keep-out area, by approximately 60% compared with Murata’s previous SWJ series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028261665/en/ [Murata Manufacturing Co., Ltd.] RF / microwave coaxial connectors with a switch As wireless devices incorporate more functionality, rising component counts are placing increasing pressure on limited PCB space. RF test connectors require not only mounting area for the connector itself, but also sufficient clearance around the component
FuriosaAI Secures $620 Million Series D to Meet Surging Enterprise AI Inference Demand and Accelerate Next-Gen Silicon29.10.2026 00:57:00 CET | Press release
Global investors, including Infinitum, Jericho Capital, QUDA Capital, Cisco Investments, and Worldline Capital, join the round alongside the National Growth Fund of Korea and Korean institutions. FuriosaAI, an AI semiconductor company building sustainable, high-performance inference compute for data centers, today announced the completion of its $620 million (KRW 820 billion) Series D round, bringing its post-money valuation to approximately $2.9 billion. The financing marks a major milestone as FuriosaAI scales global commercial deployments of its RNGD AI inference accelerator. FuriosaAI will use the new capital to expand RNGD production, strengthen its software ecosystem, and accelerate development of its third-generation AI accelerator. International investors contributed a total of $110 million to the round, bringing deep expertise across AI semiconductors and computing infrastructure. U.S.-based Infinitum, an investment firm with extensive experience in the AI semiconductor sector
IFF Declares Dividend for Fourth Quarter 202628.10.2026 21:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 13, 2027 to shareholders of record as of December 19, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20261028159928/en/
Andersen Consulting indgår samarbejde med JKIT28.10.2026 19:57:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital og forretningsmæssig transformation gennem en samarbejdsaftale med John Keells IT (JKIT), en udbyder af teknologiløsninger med base i Sri Lanka. JKIT leverer teknologirådgivning og digitale transformationstjenester til organisationer på tværs af flere brancher, herunder luftfart, finansielle tjenesteydelser, sundhedsvæsen, produktion, detailhandel og telekommunikation. Virksomhedens kompetencer spænder over forretningskritiske applikationer, cloudtransformation, cybersikkerhed, data og analyse, kunstig intelligens samt intelligent automatisering. Gennm strategiske partnerskaber med førende teknologiudbydere som SAP, Microsoft, Salesforce, Databricks og AWS hjælper JKIT organisationer med at modernisere deres teknologiske infrastruktur, effektivisere driften, styrke beslutningsgrundlaget og skabe vækst i forretningen. "Organisationer ønsker i dag at fremskynde deres digitale transformation og ai-tilpasning og har brug for ko
Transition Industries Signs Definitive EPC Agreement with Siemens Energy and Techint E&C for Pacifico Mexinol’s 210 MW Electrolyzer Facility28.10.2026 19:36:00 CET | Press release
Definitive agreement advances delivery of the electrolyzer facility supplying renewable hydrogen for ultra-low-carbon methanol production in Sinaloa, Mexico Transition Industries LLC today announced that it has signed a definitive Engineering, Procurement and Construction (EPC) agreement with Siemens Energy and Techint Engineering & Construction (“Techint E&C”) for the approximately 210 MW electrolyzer facility at its Pacifico Mexinol project in Sinaloa, Mexico. The agreement is subject to customary conditions precedent, including the completion of project financing. The signing builds on the Front-End Engineering Design (FEED) contract announced in August 2025 and represents an important milestone in advancing the project’s renewable hydrogen production infrastructure from engineering toward construction. The facility will incorporate Siemens Energy’s Elyzer P-300 electrolyzer technology and produce renewable hydrogen to support the production of renewable fuels of non-biological orig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom